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Abstract
Biobanks represent key resources for clinico-genomic research and are needed to pave the way to personalised medicine. To achieve this 
goal, it is crucial that scientists can securely access and share high-quality biomaterial and related data. Therefore, there is a growing inter-
est in integrating biobanks into larger biomedical information and communication technology (ICT) infrastructures. The European project 
p-medicine is currently building an innovative ICT infrastructure to meet this need. This platform provides tools and services for conducting 
research and clinical trials in personalised medicine. In this paper, we describe one of its main components, the biobank access framework 
p-BioSPRE (p-medicine Biospecimen Search and Project Request Engine). This generic framework enables and simplifies access to existing 
biobanks, but also to offer own biomaterial collections to research communities, and to manage biobank specimens and related clinical data 
over the ObTiMA Trial Biomaterial Manager. p-BioSPRE takes into consideration all relevant ethical and legal standards, e.g., safeguarding 
donors’ personal rights and enabling biobanks to keep control over the donated material and related data. The framework thus enables secure 
sharing of biomaterial within open and closed research communities, while flexibly integrating related clinical and omics data. Although the 
development of the framework is mainly driven by user scenarios from the cancer domain, in this case, acute lymphoblastic leukaemia and 
Wilms tumour, it can be extended to further disease entities.
Keywords: biobank access, specimen management, p-BioSPRE, ObTiMA, Trial Biomaterial Manager, IDB, p-biobank wrapper
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1. Introduction
A research-integrated biobanking solution is crucial for the advent of personalised medicine for cancer patients. Technological progress 
in cancer-related molecular biology and molecular imaging has led to an exponential increase in the possibilities for individualised cancer 
care. Moreover, the accompanying complexity of the resulting biomarkers and their application in, for instance, radiotherapy planning and 
targeted drug choice and dosing has made the knowledge base too complex for physicians and certainly incomprehensible for patients. 
Many more new potential biomarkers will be discovered in the next years, and their validation as useful biomarkers in diagnosis and therapy 
will require fast reference to the global collection of well-characterised and annotated human biospecimens. Beyond access to high-quality 
biological samples, research will also require integrated access to sample-related clinical and omics data of increasing granularity.
To address this need, a biobank access framework called ‘p-medicine Biospecimen Search and Project Request Engine’ (p-BioSPRE) has 
been designed and integrated into a general information and communication technology (ICT) infrastructure for personalised medicine, the 
p-medicine platform, aiming to cut therapy development time from bench to bedside [1]. The p-medicine platform is currently developed in 
the European project p-medicine [2] to foster research and clinical decision support for personalised therapy. This platform provides tools 
and services to semantically integrate and analyse heterogeneous biomedical data in a data warehouse. It also comprises an ontology-
based trial management system called ObTiMA [3] to design and conduct clinical trials. Within the p-medicine platform, the p-BioSPRE 
biobank access framework and the p-medicine data warehouse are foreseen to complement each other and synergise to generate and 
contribute critical Virtual Physiological Human knowledge.
The aim of p-BioSPRE is to provide access to different kinds of human biomaterials and related data for research purposes. A biobank 
operator is supported in offering his biomaterial and related data to research communities, while safeguarding donors’ personal rights and 
enabling biobanks to keep control over the donated material and related data. A researcher is enabled to search the biomaterial that is 
offered within his communities. It is furthermore possible for him to request biomaterial for a specific research project and his request is 
forwarded online to the biobank operator.
For managing biomaterial and interlinking the p-medicine data warehouse and p-BioSPRE, the ObTiMA Trial Biomaterial Manager is 
developed. It enables users of ObTiMA, the p-medicine’s ontology-based trial management system, to manage their biomaterial data within 
clinical trials. For this purpose, a pre-defined but adjustable case report form (CRF) for patient’s biomaterial is provided in ObTiMA. The 
biomaterial data can be integrated with clinical data and exported to p-BioSPRE as detailed below.
2. Methods
To build an integrated biobanking solution for p-medicine, two typical biobanking user scenarios have been analysed and user requirements 
identified. Furthermore, different tools and projects for integrated biobanking have been evaluated with the aim to find models, guidelines, 
or software that can be adapted to the biobanking user scenarios and constitute the base of an integrated biobanking framework. Based on 
these analyses, a biobank access framework has been developed in close interaction with end users and legal experts.
2.1. User scenarios
The technical development of the biobank access framework is mainly driven by two user scenarios provided by p-medicine partners in the 
context of Wilms tumour trials and clinical research, and trials related to acute lymphoblastic leukaemia (ALL). These scenarios constitute 
typical use cases for biobanking in a clinical trial setting, for any disease area whatsoever. Therefore, solutions based on these use cases 
will be generic and applicable in a wider biomedical research context.
The International Society of Paediatric Oncology (SIOP) [4] is responsible for conducting successive international multicentric Wilms 
tumour trials across Europe. Within these trials, biomaterial is collected in different participating hospitals and sent to a central national 
biorepository, where the material is stored and further analysed. Related biomaterial data are also stored at the central biorepository. 
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Currently biomaterial and data stored in the central biorepositories are not accessible via an information system from the participating 
hospitals or the study centre (central facility where the trial is coordinated). Clinical and biobanking data cannot be integrated since the 
data are stored in different incompatible systems. The data are only accessible on-site and sharing of biomaterial between international 
research partners is a very time-consuming procedure, e.g., in the German SIOP trial, the central biorepository is located at the Biocenter 
of the University Würzburg. Data about the biomaterial are captured in several spreadsheets in Würzburg, e.g., analysis information or 
information about the quality of the biomaterial. Clinical data are collected in the web-based trial management system ObTiMA that is 
hosted at the study centre at the University Homburg, e.g., information about the patient’s clinical data including chemotherapy, surgery, 
and radiotherapy, but also pathology data and outcome data. Biomaterial data stored in the spreadsheets and clinical data stored in 
ObTiMA cannot be integrated automatically into one platform. In addition, there is no query tool available that allows searching for specific 
biomaterial samples. Questions like ‘How many samples are available from female patients that have stage I tumours having relapsed 
and having not relapsed?’ are not resolvable so far. Even access to the data and further statistical analysis of the data cannot be done by 
the study centre in Homburg, as long as these data are stored in independent databases.
The International BFM Study Group (I-BFM SG) [5] is dedicated to promote both research and clinical care for patients with leukaemia 
and lymphoma. A growing number of participating national study groups from meanwhile more than 30 countries worldwide collaborates in 
multicentric trials in the field of leukaemia and lymphoma, e.g., around 80% of childhood ALL patients in Germany are included in ALL-BFM 
trials, which are coordinated by the University Hospital Schleswig-Holstein of the Christian-Albrecht-Universität zu Kiel. If ALL patients, who 
were treated in an ALL-BFM study, relapse, they are usually treated according to ALL-REZ BFM protocols. ALL-REZ trials are coordinated 
by the Charité Universitätsmedizin Berlin.
Currently, BFM partners can only access clinical data and biomaterial data of their own patients stored in their own local databases. In 
particular, it is not possible for the ALL-REZ BFM study centre in Berlin to access their patients’ biomaterial of initial diagnosis and data in 
the study centre in Kiel online. Regarding European and worldwide collaborations for research on ALL, it is highly desired to access and 
share biomaterial and related analytical data within the respective international research community. 
Therefore, the following generic needs have been identified for the p-BioSPRE biobank access framework (and beyond):
•	 The	international	study	groups	need	to	integrate	biomaterial	repositories	to	be	able	to	share	biomaterial	and	data	within	national	and	
international research communities. This is currently not possible but required to foster research in the field of personalised medicine. 
In particular:
- Biobank operators need to offer their biomaterial and data that are stored in legacy biobank management systems to research 
communities.
- Researchers need to search for and request specific human biomaterial that is appropriate for their research.
•	 It	is	necessary	to	integrate	biomaterial	data	with	corresponding	clinical	and	omics	data	preferably	over	the	same	information	system.
Patients’ privacy and autonomy, as well as researchers’ and biobanks’ confidentiality and autonomy must be safeguarded at any time.
In addition, requirements specific for the SIOP and I-BFM SG communities, including data structure and existing software and database 
architecture must also be fulfilled in a flexible manner, allowing p-BioSPRE to integrate further (and so far unknown) biobank partners 
consecutively.
2.2. Evaluation of tools and guidelines
There are numerous tools and projects that focus on the integration of biobanks. We have evaluated many different approaches with the 
aim to find models, guidelines, or software that could be adapted to the biobanking user scenarios described in the last section, and consti-
tute the base of an integrated biobanking framework in the p-medicine platform (see Table 1 and [6] for an overview). To confine adaptation 
efforts, flexibility and interoperability of these tools with local biobank information management systems, which already pre-exist with use 
case partners, are of paramount importance. This flexibility was given highest priority for the evaluation summarised in Table 1, and it was 
found to be fulfilled best by the CRIP tools. Furthermore, we have drawn two main conclusions that we outline in the following.
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- Though Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) is not operable yet, it is of outmost importance 
that the results of the preparatory phase of the BBMRI project [7] be considered when developing p-BioSPRE. BBMRI aims to build a 
European biobanking research infrastructure, and they have diligently elaborated requirements and criteria for integrated biobanking, 
which have already been implemented in Nordic countries [8, 9]. It is foreseen that BBMRI will be implemented in the future under 
the European Research Infrastructure Consortium legal entity. As of 14 October 2013, final approval of this entity by the European 
Commission is expected for autumn 2013.
- As mirrored by the BBMRI list of requirements (cf. [6] chapter 5.2.2) and confirmed by our analysis of legal interoperability below, 
a trans-institutional or even transnational biobanking platform can practically only be operated on anonymised data (processing of 
personal data is only allowed under certain circumstances, see page 20), which should be displayed in statistical groups only. Among 
all the tools and guidelines, which we have evaluated (Table 1, [6]), only the CRIP concept [10] fulfils this critical requirement. All the 
other tools and suites, such as the caBIG Tissue Banks [11] or i2b2 [12], are more or less centralised biobank and data management 
systems processing pseudonymised data. Referring to the European Union (EU) Data Protection Directive (see Section 2.3 below), 
pseudonymised data are as a general rule to be regarded as personal data (for more information see Art. 29 Working Party, Opinion 
4/2007 on the concept of personal data, http://ec.europa.eu/justice/policies/privacy/docs/wpdocs/2007/wp136_en.pdf, pp 18–20), 
and hence strict requirements of the specific applicable national data protection laws would have to be met, which in effect would 
amount to a serious obstacle for transnational data transfer.
CRIP is a model for a meta biobank [10] that has already been adapted for a central national German biobanking infrastructure [13, 14], 
and shortlisted by the STRATUM project as a system for the development of a UK biobank catalogue for biomedical research [15]. Hence, 
we have selected the CRIP toolbox [16] as a base for p-BioSPRE since it is in line with BBMRI’s recommendations on federated biobanking 
infrastructures, adaptable to all needs of the user scenarios and furthermore in a productive state since 2006.
Table 1. ICT tools for integrated biobanking (overview; see [6] for further details).
Tool/Acronym URL Characteristics Aspects regarding p-BioSPRE
caTissue Suite
https://cabig.nci.nih.gov/tools/catis-
suesuite, accessed 31/10/2011 and 
27/11/2013
NCI initiative; centralised sample 
inventory/manual annotation; open 
source
Questions on user friendliness and  
maturity raised by evaluation reporta. 
Anonymisation questionable
BBMRI Preparatory 
Phase; WP 5
http://www.bbmri.eu/index.php/ 
workpackages/wp-5,
accessed 31/10/2011
EU—FP 7 project aiming to build a 
pan-European biobanking research 
infrastructure
Concepts, but no tools available
i2b2
http://www.i2b2.org/,
accessed 31/10/2011 and 
27/11/2013
‘Informatics for Integrating Biology 
and the Bedside’; open source
Adaptation for biobank access required. 
Changes and exchanges have to deliver 
to the Brigham and Women’s Hospital Inc.
SIMBioMS
http://simbioms.org/;
accessed 31/10/2011 and 
27/11/2013
Web-based open-source software  
system for managing data and  
information in biomedical studies; 
SAIL subsystem for biobank access.
Deeper technical information needed. 
SAIL provided under the GNU GPL 
licence: Implications for p-BioSPRE 
exploitation
P3G DataSHaPER
http://www.datashaper.org/;
accessed 31/10/2011 and 
27/11/2013
Tools to foster interoperability of  
epidemiological cohorts and  
population-based biobanks
Epidemiological tool: adaptation to 
disease-oriented biobanks would  
be required
CRIP Toolbox
http://www.crip.fraunhofer.de/;
accessed 31/10/2011 and 
27/11/2013
Proprietary tools of Fraunhofer 
IBMT; operative since 2006 and  
approved by German data  
protection authorities
Tools available, operative, and tested since 
2006. Modularity of software allowing 
for flexible solutions in different settings. 
Anonymisation/privacy regime approved 
by German data protection authorities
BBMRI: Biobanking and Biomolecular Resources Research Infrastructure.
p-BioSPRE: p-medicine Biospecimen Search and Project Request Engine.
EU: European Uninon.
ahttp://deainfo.nci.nih.gov/advisory/bsa/bsa0311/caBIGfinalReport.pdf; accessed 27/11/2013.
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2.3. Legal interoperability
Apart from the technical aspect of transnational and interoperable biobanking infrastructure, the legal framework is also an important factor 
to consider when developing a solution to the problems identified above. This is because biobanks and clinical research centres operate 
under strict rules in terms of biomaterial handling as well as processing of sensitive personal data associated with the biomaterials. These 
rules are to a large extent not harmonised within the EU, which means that in practice, different legal regimes apply for the use of the 
samples for research on the one hand, and the processing of associated personal data of the donors on the other hand. As a result of this, 
any platform that tends to integrate biobanking infrastructures across Europe will have to comply with multiple laws, or at least, aim at fulfill-
ing the requirement of the regime with the highest threshold. Although national laws implementing the Data Protection Directive (Directive 
95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing 
of personal data and on the free movement of such data) are in a more coherent framework (it should be noted that implementing the Data 
Protection Directive into 28 EU member states laws has also resulted into some remarkable differences in the national data protection 
laws), there is, however, no such coherent framework on a European level for the sharing of biomaterial. 
However, to implement the objectives of the p-BioSPRE meta biobank, relevant national legal regimes implementing the Data Protection 
Directive, and the biobanking laws were considered. In this regard, one elementary aspect of consideration is the scope of application of 
national data protection laws. Those only apply to the processing of personal data (see Art. 3 Data Protection Directive), which is defined 
as: ‘any information relating to an identified or identifiable natural person (‘data subject’); an identifiable person is one who can be identified, 
directly or indirectly, in particular by reference to an identification number or to one or more factors specific to his physical, physiological, 
mental, economic, cultural, or social identity’ [Art. 2 lit. (a) Data Protection Directive]. This definition is broad, encompassing every con-
ceivable data that refer to a person. This means that as long as a person can be identified with reasonable means from data that are, for 
example, held in an electronic patient record, this data are regarded as personal data. All kinds of data, such as clinical data (e.g., clinical 
laboratory test results, patient demographics, pharmacy information, and radiology reports), data from biomaterial that could be linked to 
an individual, and so on, will fall into this category. To determine whether a person is identifiable, account has to be taken of all the means 
likely reasonably to be used either by the controller or by any other person to identify the said person (Recital 26 Data Protection Directive; 
according to the Art. 29 Working Party, one should in particular consider all the factors at stake: e.g., the cost of conducting identification, 
the intended purpose, or risks of organisational dysfunctions and technical failures; Opinion 4/2007 on the concept of personal data, viewed 
25.11.2013, <http://ec.europa.eu/justice/policies/privacy/docs/wpdocs/2007/wp136_en.pdf>). This broad criterion means that only a narrow 
segment of data could fall outside the scope of personal data. 
Anonymisation of personal data (it is controversial if anonymisation of personal data is to be seen as a form of processing of personal 
data, see [17] pp. 42–43.) appears to be the only solution that permits processing in complex situations, which consequently eliminates the 
requirement to comply with the strict standards applicable to processing of personal data (it is even legally required to keep data no longer 
in a form that permits identification of data subjects for longer than necessary for the purposes for which the data were collected or for which 
they are further processed, see Art. 6 (e) Data Protection Directive). However, it is not an easy task to achieve such complete anonymity, 
especially with respect to the fast moving developments in data linking and mining technology. This means that the anonymous status 
can swap quickly into a personal one. This can only be forestalled by regular evaluations of the risk of reidentification of the data. This risk 
can be decreased and controlled by a number of technical and organisational measures, such as restricting access and access controls, 
strong passwords registration procedures, and contractual agreements. To handle these issues, a legal and contractual framework has 
been developed along with the ICT infrastructure for p-BioSPRE that provides the base for secure and legally compliant biomaterial and 
related data sharing.
After careful evaluation, we decided that the legal framework setup for the meta biobank will operate with anonymous data. In this case, 
the strict standards applicable to processing of personal data have not to be considered because the national laws implementing the 
Data Protection Directive do not apply. In addition, the contractual framework aims at securing this anonymity to achieve a compliant 
biomaterial and data sharing framework favourable to all jurisdictions. A detailed discussion on the legal and contractual framework is 
given in Section 3.2.
To enforce patients’ decision on the research use of their specimens, and to prepare for existing privacy regulations [18], p-BioSPRE will 
be equipped to record tiered informed consent and provide this information, if available, for the meta biobank query.
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3. Results: the p-BioSPRE biobank access framework
Based upon analysis of the two user scenarios, we have designed the p-BioSPRE biobank access framework to provide registered 
researchers access to different kinds of human biomaterials and related data. Starting with a minimum dataset (Table 2), the framework 
provides means to harmonise data (see Section 3.1.2) and facilitates data import by help of a metadata repository (MDR). 
Only the six items constituting the minimum dataset (bold text in Table 2) must be mandatorily provided by the biobank partners, keeping 
the threshold low for them to participate. Although overlap with the MIABIS minimum dataset [19] proposed for BBMRI is small so far (cf. 
Table 2), it can easily be completed upon the biobank partners’ request. Numerous additional data fields shown in Table 2 emerged from 
the ALL-BFM and ALL-REZ BFM databases and can at any time be changed or extended without programming efforts over the MDR (cf. 
Section 3.1.2). Once integrated, all data fields are displayed over the p-BioSPRE search tool (see Section 3.1.1).
Table 2. Minimum dataset (in bold) and metadata (in alphabetical order) of p-BioSPREa
Description Name Type
Age of donorb age int
Biobank acronym biobank text
Name of contact person (7) biobank_contact text
e-mail address of contact person (9) biobank_email text
Name of biobank (2) biobank_name text
blasts_bm text
blasts_pb text
crlf2 text
cytological_response text
Date of birth (full years only) dateofbirth date
Date of sample preservation dateofsamplepreparation date
Diagnosis diagnosis text
Class of code diagnosis_class text
Code of diagnosis diagnosis_code text
epigenetic_platform text
epigenetic_profiling text
exom_sequencing_platform text
extramedullary_compartment text
gene_expression_platform text
gene_expression_profiling text
genetic_subtype text
genome_sequencing_platform text
Group of material groupofspecimen text
ikzf1 text
immunophenotype text
labeldateofbiopsy text
leukocytes text
localisation text
localisation_class text
localisation_code text
micro_rna_platform text
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Table 2. Continued.
micro_rna_profiling text
mlpa_kit text
mlpa_screening text
mrd_response text
notch1 text
Patient ppsn text
prednison_response text
Case psn text
Sex of donor sex text
snp_diagnose text
snp_platform_diagnose text
snp_platform_remission text
snp_remission text
stage text
stratification text
tp53_diagnose text
tp53_remission text
tpmt text
trial text
trial_follow_up text
Material type (41); typeofspecimen text
whole_exome_seq text
whole_genome_seq text
aMinimum data include: diagnosis_class (standard used, e.g., ICD-O or ICD-10);  
diagnosis_code (actual code, e.g., C64 for malignant neoplasms of kidney); group of  
specimen (e.g., blood, tissue); ppsn (patient); and psn (case). A patient can constitute  
several cases, and a case can be backed by several specimen types and aliquots.
Where applicable, attribute numbers as listed by MIABIS [19] are given in brackets behind 
the description of data fields.
bcalculated from year of birth and year of sample preservation.
In particular, the p-medicine biobank framework supports the following main functionalities:
(a) Offering human biomaterial for research
A biobank operator is supported in providing data on his biomaterial and related clinical data to open or closed research communities, 
as defined in p-BioSPRE. Data provision is regulated in p-BioSPRE’s legal framework especially by p-medicine’s Biobank Data Transfer 
Agreement (see Section 3.2). Any biobank management system can be used to import data into and anonymise data within p-BioSPRE. 
It is up to the operator to decide upon research communities to whom his data will be disclosed (or not), and upon his response to incom-
ing project requests. This ensures full control over his material and data.
(b) Requesting specific human biomaterial for research purposes
A registered researcher is enabled to search for and request biomaterial that is available within his research communities. He can 
access information about data linked to biomaterial and the number of available cases (a case (‘psn’ in Table 2) is defined as the data 
belonging to a specific disease of a donor/patient) backed by specimens. The p-BioSPRE web portal enables researchers to define a 
search profile according to the classification and annotations stored in the underlying database. The result of queries is presented as 
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statistical groups, based on a k-anonymised view on the data. The project portal allows selection of statistical groups from the search 
result. Researchers are then requested to describe the scope of the envisioned project and can specify additional services (e.g., poly-
merase chain reaction, immunohistochemistry, fluorescence in situ hybridisation; see Figure 4, ‘Requested Methods’). Upon submission 
of the project request, the providing hospital or consortium will be displayed.
(c) Managing biomaterial data in ObTiMA
Users of ObTiMA, the p-medicine’s ontology-based trial management system, can manage their biomaterial data within clinical trials. For 
this purpose, a pre-defined but adjustable CRF for patient’s biomaterial is provided in ObTiMA, the so-called biobanking specimen CRF. 
The biomaterial data can be integrated with clinical data within a trial or across several trials for further analysis. The collected biomate-
rial data can be shared by uploading it into p-BioSPRE. Legacy biomaterial data can be imported into ObTiMA from excel files. 
Altogether, p-BioSPRE is compliant with the aforementioned BBMRI list of requirements for data integration systems ([6] chapter 5.2.2), 
including (among others)
•	 compliance	with	local	database	policies,	national	ELSI	regulations	and	EU	data	protection	regulations	(R	1);
•	 user	authentication	and	authorisation	(R	9);
•	 full	control	of	local	biobanks	on	the	data	they	expose	(R	14);
•	 anonymisation/k-anonymisation	of	data	and	metadata	(R	15,	R	16);
•	 metadata	driven	query	and	analysis	tool,	not	custom-written	against	a	fixed	data	model	(R	27).
3.1. p-BioSPRE software components
We have designed the biobank access framework as a set of coupled components, which are shown in Figure 1.
Figure 1. Basic architecture of the p-medicine biobank access framework.
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The main component of the framework is p-BioSPRE, which is a meta biobank to share biomaterial for research purposes. p-BioSPRE is 
based on the CRIP meta biobank [10]. Furthermore, the framework comprises the p-biobank wrappers, which are tools to support biobank 
operators to make their biomaterial and related data available in p-BioSPRE and to manage associated requests, independent from their 
underlying biobank management system. This is achieved by the core of each p-biobank wrapper, the local In-house Database (IDB), a 
component of the CRIP Toolbox [16]. To enable users of the p-medicine trial management system ObTiMA, to integrate biomaterial data in 
clinical trials, and to offer them in p-BioSPRE (via the p-biobank wrappers), a Trial Biomaterial Manager is provided. 
In the following, we will describe the functionality of the different components in more detail.
3.1.1. p-BioSPRE: the p-medicine biomaterial search and project request engine
p-BioSPRE is a meta biobank that provides researchers the possibility to search for and request biomaterial that fits their research purposes.
Technically, p-BioSPRE is based on the CRIP meta biobank [16]. It is a web application and database architecture and it can be accessed 
via the p-medicine portal, the main access point of the p-medicine platform.
Database architecture
From the biobank operators' local IDBs (see Section 3.1.2) data are uploaded to the p-BioSPRE central database. The anonymised data 
are encrypted via SSL protocol and then uploaded to the central database, which is hosted at Fraunhofer IBMT. Before upload, biobank 
operators need to authenticate. In the central database, each subsequent upload will completely replace the previous one of this biobank 
partner ensuring that cases (cf. Table 2) cannot be traced back. Although search in the central database is performed on anonymised 
cases, the result is in addition displayed as pools of cases/statistical data only (see text below and Figure 3). This design delivers, through 
a differentiated query of granular, yet anonymised data, a comprehensive and satisfying result (Figures 3 and 4) to the p-BioSPRE user, 
though compliant with all privacy and data protection requirements (cf. Section 3.2).
p-BioSPRE search tool
p-BioSPRE provides a search interface that enables authorised users to search for biomaterial. After authentication, users access an 
interactive search tool (Figure 2) allowing to select:
•	 diagnosis (based on ICD 10 and ICD-O);
•	 specimen (type of specimen, e.g., whole blood, serum, tissue (FFPE or cryo-preserved), DNA, RNA, etc.);
•	 patient data (age, sex, body mass index (BMI), etc.);
•	 annotation (including clinical information and genetic subtypes);
•	 consent (information on patient’s informed consent given for the underlying biobank/trial).
Although initially only cases of Wilms tumour and ALL will be processed in p-medicine, the system is open to integrate and display all diag-
noses, as technically provided by the CRIP concept. 
Once the user has selected appropriate criteria (‘strata’, cf. Figure 2a) for his envisioned project, the ‘continue’ button will open up the list 
of ‘pools’ (Figure 3) or, in other words, of (statistical) groups of cases matching the user’s request. Although providing the user with the 
sought-after information how many cases and specimens would be available for his/her project, tracking of single cases or patients will 
obviously not be possible over the p-BioSPRE search tool. Hence, the statistical (or ‘aggregated’) data shown on the p-BioSPRE pool 
list are fully in line with data and privacy protection requirements. This design allows a maximum protection of privacy-related interests of 
donors, in particular anonymity of donors within the p-BioSPRE infrastructure, whereas at the same time access to information on available 
specimen is provided.
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 (b)
Figure 2. p-BioSPRE search tool. (a) Search criteria can be entered under five tabs representing multiple options each. Selected criteria are shown 
in the box ‘Your selection’, overall number of available matching cases just above. (b) Annotation of specimens includes clinical, cytogenetic, and 
omics data. The selection of parameters shown here is representing the ALL dataset and can be extended for any other datasets if required.
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Figure 3. p-BioSPRE pool list. Upon ‘continue’, the pools selected by requesting a number of cases (‘Required Datasets’, left column) are auto-
matically inserted into the Project Request Form (Figure 4). Note that pools shown in this screenshot are small since to date only 50 datasets 
have been imported into p-BioSPRE. Display of minimum number of datasets in a pool can be set by default (see Section 3.1.2, elements of 
k-anonymisation).
Figure 4. p-BioSPRE project request form. Submission of the ‘Project Request Form’ generates a file with the search profile that is automatically 
conveyed to the participating biobank partners. Requested biobanks will run this ‘input file’ on their local IDB (Figure 5; button ‘Project request’) 
and retrieve a list of pseudonymised cases matching the project request.
When a user has found appropriate biomaterial for his research, he can request it over an interactive request form (Figure 4) enabling him 
to specify the amount of biomaterial he needs and to outline his research project in some detail (i.e. as far as relevant for the biobank). 
Having submitted his project request, a receipt window will open up to the user indicating the biobank operator(s) to whom his request has 
been forwarded. He is then free to contact them directly or await their response within ten workdays, as agreed over the Biobank Data 
Transfer Agreement (see Section 3.2, ‘The request procedure’).
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Figure 5. p-Biobank wrapper user interface: management of IDB. Functionalities of buttons are as follows: 1) insert biobank data: select and 
import a data file; 2) anonymise biobank data: deidentify data and create a file ready for export to p-BioSPRE; 3) browse biobank data: View cases 
(e.g., to restrict export); and 4) project request: execute a project request (file) and retrieve cases matching the request.
p-BioSPRE forwards the request as an xml file to the biobank operator enabling him to quickly retrieve the requested material over his/her 
p-biobank wrapper. In other words, the result of the project request tool is a search profile that can be applied on the data stored in the IDBs 
of the p-biobank wrapper, delivering the list of locally available cases matching the user’s project request/search criteria. The biobank can 
then contact the researcher and decide about the request.
3.1.2. p-Biobank wrappers
Biomaterial data are uploaded into p-BioSPRE from so-called p-biobank wrappers. Technically, a p-biobank wrapper is based on the 
IDB, a component of the CRIP toolbox that comprises a local database, software, and web services that can be installed at the biobank 
operator’s site. 
A p-biobank wrapper provides biobank operators a comfortable user interface to share their biomaterial and related data in p-BioSPRE (cf. 
Figure 5).
It imports pseudonymised data on biomaterial and provides a selected, anonymised export file to p-BioSPRE for online queries (Figure 5, 
buttons ‘Insert biobank data’ and ‘Anonymise biobank data’). Upon import, data are harmonised (e.g., by unifying different formats for time 
stamps or for sample donor’s sex (male/female; m/f, etc.), and deidentified, e.g., by stripping off identifiers or pseudonyms and by converting 
a patient’s exact age into full years. Further features of the the p-biobank wrappers are
•	 elements	of	k-anonymisation	(see	below)	[20];
•	 calculation	of	values	(e.g.,	age	of	patient	from	dates	of	birth	and	sample	preservation,	or	of	BMI	from	patient’s	height	and	weight);
•	 MDR.
Because of the MDR, p-biobank wrappers can easily be adapted to the export functionality of the biobank information management system: 
the MDR just needs to be configured accordingly without any programming efforts.
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The user model of the p-biobank wrappers provides roles for 
•	 one	or	more	biobank(s)/user(s)	(import/export/search	data);
•	 an	administrator	(delete	data	from	database/add	users/add	biobanks).
Data will not be exported automatically to p-BioSPRE, export can only be triggered by the participating biobank operators (cf. Figure 5, 
button ‘Anonymise biobank data’). Thus, before data will be sent to the p-BioSPRE database, all identifying data will be stripped off, and no 
personal information will be transferred. 
Elements of k-anonymisation
Some p-BioSPRE features towards an approach for k-anonymity, or to depersonalise data at least by widening the interval that is being 
processed or displayed for this data, have already been mentioned in the text above: A patient’s exact age is always converted into full 
years already upon import into the p-biobank wrapper. In addition, over the p-BioSPRE search tool, a minimum of five-year intervals may 
be selected for sample donor’s age.
As shown in the legend of Figure 3, a minimum number of datasets in a pool can be set by default in the search tool, and in the IDB as 
well. In the search tool, this would prevent any pools below a certain limit from being displayed. In the IDB, this feature allows implement-
ing specific requirements of local Ethics Review Boards prescribing that a pool must contain, for example, a minimum of five cases to be 
processed, safeguarding that projects based on a smaller number of cases cannot be performed.
3.1.3. ObTiMA trial biomaterial manager
The Trial Biomaterial Manager is developed as a component of the web based trial management system of the p-medicine infrastructure 
ObTiMA [3]. It enables management of biobanks and associated specimen data in clinical trials and sharing selected specimen data.
The Trial Biomaterial Manager provides users an interface to manage specimen data in clinical trials. For this purpose, a predefined 
biobanking specimen CRF that allows users to collect different kind of specimen information is provided that can be adjusted to the user’s 
needs. This CRF is stored in the ObTiMA CRF Repository [3], a repository for reusable patient CRFs. 
An interface is provided to get an overview of the available biomaterial. Furthermore, it is possible to link clinical data and biomaterial data 
within clinical trials.
Optionally, a biobank can share selected data on biomaterial by uploading it via the p-biobank wrapper anonymised to p-BioSPRE. In the 
following, the current functionality of the Trial Biomaterial Manger is described in more detail.
Managing biobanks
The Trial Biomaterial Manager provides biobank operators the possibility to create virtual biobanks, edit and view the biobank metadata, 
and manage the samples of the biobanks. Furthermore, biobank operators can assign trials to the biobank and specify and control, which 
ObTiMA users may access the data of the biobank.
In Figure 6, the user interface to edit the metadata of a biobank is shown. The metadata can be edited under several tabs. In the tab 
‘Biobank Details’, the main metadata for the biobank can be filled in by the user. The biobank details comprise:
•	 General	Information	as	the	name,	the	biobank	operator,	and	the	location	of	the	biobank.
•	 Specification	of	the	provided	services,	e.g.,	the	specification	of	the	storage	cost	and	if	the	biobank	is	used	commercially.
•	 Specimen	information	as	the	number	of	specimens	that	can	be	stored	and	the	number	of	specimens	that	are	being	stored	at	present.
•	 Detailed	information:	additional	information	about	the	biobank,	e.g.,	the	homepage	and	the	contact	mail.
•	 Tissue	information:	information	about	the	tissue	types	stored	in	the	biobank.
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Figure 6. ObTiMA Trial Biomaterial Manager.
Furthermore, the user can list the members of the biobank committee. It is possible to assign biobanks to trials in order to enable collection 
of biomaterial for the biobank in different trials. In ObTiMA, specimens are created in trials to simplify the integration with the clinical data 
collected in the trial. A specimen that is created in a trial can be assigned to a specific biobank, but only if the biobank has been previously 
assigned to the trial. The assignment of the biobank to the trial needs to be confirmed by the trial chairman.
A biobank operator can also assign ObTiMA users permissions to manage the biobank, e.g., editing metadata for the biobank or viewing 
specimens. A user with the latter permission can only view specimens that are stored in the biobank. By clicking on a specimen, the user 
is directed to the CRF in the appropriate trial, where the specimen has been created and can access clinical as well as specimen data of 
the patients.
Creating specimens and biobanking specimen CRF
A specimen can be created by assigning the biobanking specimen CRF to a patient (Figure 7). This CRF is stored in the ObTiMA CRF 
Repository. On this CRF, relevant information describing a biobank sample can be collected on items that are structured into the following 
sections and subsections:
•	 General:	general	information	about	the	specimen,	e.g.,	information	about	informed	consent	or	storage	location.
•	 Material:	material	type,	e.g.,	blood	or	tumour	tissue,	and	depending	on	the	material	type	items	to	characterise	the	material,	e.g.,	the	
total volume of collected blood or the available volume for material type blood.
- Transport, processing, and storage: quality information about the transport, processing, and storage, e.g., the processing method 
or the freezing temperature. 
- Vials: information about the available vials, e.g., when the material in the vials was isolated.
•	 Analyses:	 information	about	 the	analyses	made	with	 the	specimen,	e.g.,	 information	about	 the	normalisation	and	the	used	
platform.
A precondition to create a specimen in a trial is adding the biobanking specimen CRF to the trial in the design phase and adapt it to the trial’s 
needs. For this purpose, ObTiMA provides a user-friendly interface that allows adding, changing, and/or deleting items on a CRF. 
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Figure 7. Biobanking specimen CRF.
The mechanism to store sample data on CRFs simplifies the integration with clinical data that are as well stored on patient CRFs. It is possible 
to explore patient’s biobanking and clinical data in ObTiMA. Furthermore, the data can be exported in one file for further analysis.
Shipping biomaterial
The Trial Biomaterial Manager supports also the process of shipping biomaterial samples from a study centre to a biobank operator. The 
biobank operator must not know the identifying data of the patient. Therefore, when shipping the biomaterial, the study centre needs to 
send the pseudonym to the biobank operator to enable matching the referenced patient in ObTiMA. Barcode labels are used to facilitate 
handling of the very long pseudonyms. For this purpose, a study centre can print a barcode for the patient and label the specimen for trans-
port to the biobank operator. In turn, the biobank operator can find the referenced patient by simply scanning the barcode. 
Interface to p-BioSPRE and the p-medicine data warehouse
Interfaces to p-BioSPRE and the p-medicine data warehouse are provided (cf. Figure 1). A trial chairman or biobank operator can export 
the specimen data of a trial to make it available in p-BioSPRE. To this end, the pseudonymised biobanking data can be exported into a file 
in CDISC ODM format [21], a standard format for exchanging trial data and seamlessly upload it into a p-biobank wrapper installation. The 
Trial Biomaterial Manager integrates push services that are used to push selected biomaterial data into the p-medicine data warehouse. 
Here, the data can be seamlessly integrated with heterogeneous biomedical data, e.g., clinical or microarray data, and subsequently it 
can be analysed with the tools provided by the p-medicine platform. Thus, the push services interlink the p-medicine data warehouse and 
p-BioSPRE.
3.2. Legal framework for biomaterial sharing
Alongside the ICT framework, a legal framework has been provided for p-BioSPRE to ensure compliance with applicable regulations. This 
framework deals with data protection and data security issues within the p-BioSPRE meta biobank, and regulates the relationship between 
the actors: meta biobank operator, biobank operators, and researchers. In the following, we describe the most important aspects of this 
legal framework.
Re
vi
ew
 16 www.ecancer.org
ecancer 2014, 8:401
Data protection and data security
National data protection laws implementing the Data Protection Directive have been considered when developing the p-BioSPRE meta 
biobank architecture. This is important because processing of personal data is prohibited unless informed consent of the concerned person 
has been obtained or a national provision, implementing the Data Protection Directive, allows such data processing (Art. 7 and 8 (Art. 8 
Data Protection Directive include health data or data revealing racial or ethnic origin as sensitive data) of the Data Protection Directive). It 
is usually difficult to fulfil the rigorous requirements associated with processing of sensitive personal data, and where permissible, research-
ers resort to using anonymous data, that is, data considered as not identifying any person, although it is still controversial whether certain 
types of data, such as genetic data, can be truly anonymous [22]. However, anonymous data would not be considered as ‘personal data’ in 
the sense of Art. 2 lit. (a) of the Data Protection Directive, with the consequence that the Directive and the implementing national laws on 
processing of personal data do not apply (See Section 2.3).
On the basis of the above, the data flow within the meta biobank infrastructure has been designed so that p-BioSPRE processes only 
anonymised data, and displays statistical data that do not reveal any individual identity when performing a search. Both measures are 
complemented by introducing elements of k-anonymity as described above (see. Section 3.1.2).
In addition, a Biobank Data Transfer Agreement between the meta biobank operator and the biobank operator has also been introduced. 
This agreement includes an obligation on the meta biobank operator to import only anonymised data, and to refrain from reidentifying or 
matching datasets to reveal individual identities. In addition, a p-medicine meta biobank access policy has been developed as part of the 
organisational measure to control the context in which data are processed. In essence, access to the meta biobank is restricted to only 
registered researchers whose identity, institutional affiliations, and research interests have been verified by the p-medicine meta biobank 
operator. To register, researchers need to download a form, fill it in, and send it to the meta biobank operator. With the latter, staff (four-eye 
principle) will check the registration form for completeness and plausibility and document their approval before assigning password and 
username to the applicant.
Furthermore, confidentiality and security are guaranteed by an advanced security solution that relies on the p-medicine security framework. 
The p-medicine security framework is based on open commonly used stable standards, such as SAML 2.0 [23], SSL, and X.509 (X.509 is a 
standard for public key infrastructure: http://datatracker.ietf.org/wg/pkix/charter/). The framework provides features, e.g., brokered authen-
tication for services and an extended roles and rights system. It restricts access only to authenticated users who have sufficient access 
rights and ensures that all communication is encrypted through SSL.
A detailed description of the p-medicine security framework can be found in [24]. The integration of the p-medicine security framework into 
the legal framework for p-BioSPRE is described in [25]. In this document, it is especially outlined in detail how p-BioSPRE uses the bro-
kered authentication of p-medicine via a gateway solution to guarantee secure access only for authorised users.
Informed consent
The nature, design, and scope of consent that was obtained during the collection of biosamples are part of the critical factors in allowing 
access to the samples stored in biobanks. It is of utmost importance that the consent form has clear rules and conditions of sharing data 
and biosamples to avoid a future problem in reusing the samples for other researches. Researchers need to be aware of the secondary 
use-problem limiting research and data processing for a purpose that was not foreseen when collecting the sample and data. This problem, 
however, goes beyond the legal framework developed for p-BioSPRE. The framework here covers access to data about existing biomaterials 
only. The exchange of physical material is not part of the overall framework because in practice, it is subjected to bilateral material-transfer 
agreements between the biobanks and the requesting researchers. 
Data on informed consent (“IC data”) are integrated into p-BioSPRE (cf. Figure 2). This will on the one hand enable biobanks to internally, 
check whether the consent will cover a requested research project, enabling them to inform external researchers as early as possible if the 
request will be granted or not.
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The request procedure
Researchers will also have the opportunity to request for material over the meta biobank portal. This request will be forwarded to the 
responsible biobank operator, thus facilitating the negotiation process for material transfer. The biobank operator and the researcher then 
need to agree on the conditions under which the samples will be provided considering the applicable national legislations. The p-medicine 
Biobank Data Transfer Agreement includes clauses on the procedure and time frame for response to the request by biobank operators. For 
example, it is envisaged that an answer to the access request shall be given in reasonable time, not later than ten working days after receiv-
ing the request though the p-medicine meta biobank. A detailed description of the legal framework for p-BioSPRE can be found in [25].
4. Conclusion
p-medicine’s biobank access framework p-BioSPRE is an integrated biobank solution to support research in personalised medicine. It 
enables and facilitates secure transnational access to existing biobanks, but also offering biomaterial collections to research communi-
ties. Biobank specimens can be managed using the ObTiMA Trial Biomaterial Manager. Along with biobank data, information on patients’ 
informed consent is also processed and displayed. The development of p-BioSPRE is driven by two user scenarios on ALL and Wilms 
tumour, to seamlessly adapt the framework to the needs of integrated biobanking. 
The biobank access framework is integrated into the p-medicine platform, enabling that biobanking data can be integrated with hetero-
geneous biomedical data, e.g., clinical or microarray data, and subsequently can be analysed with the tools provided by the p-medicine 
platform.
An initial version of the biobank access framework is available on a test server of the p-medicine portal, the main access point of the 
p-medicine platform, and can be evaluated by interested research communities under the URL https://pmedportal.ibmt.fraunhofer.de. 
In the next months, it will be evaluated by the SIOP and the ALL study groups. Components of the framework will then be further adapted 
to user needs and improved with additional features.
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